WallStSmart

Ascendis Pharma AS (ASND)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ascendis Pharma AS generates 141008% more annual revenue ($1.05B vs $742,000). ASND leads profitability with a 70.9% profit margin vs 0.0%. ASND earns a higher WallStSmart Score of 61/100 (C+).

ASND

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 9.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: -2.66

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASND4 strengths · Avg: 10.0/10
Return on EquityProfitability
52.6%10/10

Every $100 of equity generates 53 in profit

Profit MarginProfitability
70.9%10/10

Keeps 71 of every $100 in revenue as profit

Operating MarginProfitability
65.0%10/10

Strong operational efficiency at 65.0%

Revenue GrowthGrowth
114.7%10/10

Revenue surging 114.7% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ASND4 concerns · Avg: 3.3/10
Price/BookValuation
10.4x4/10

Trading at 10.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
-2.662/10

Distress zone — elevated risk

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ASND

The strongest argument for ASND centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 70.9% and operating margin at 65.0%. Revenue growth of 114.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ASND

The primary concerns for ASND are Price/Book, EPS Growth, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

ASND profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ASND is growing revenue faster at 114.7% — sustainability is the question.

ASND generates stronger free cash flow (283M), providing more financial flexibility.

Bottom Line

ASND scores higher overall (61/100 vs 24/100), backed by strong 70.9% margins and 114.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ascendis Pharma AS

HEALTHCARE · BIOTECHNOLOGY · USA

Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?